Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
NCT05316220 · AbbVie · PHASE3 · withdrawn · last registry update 2025-08-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “strategic considerations” | – | Registry record, AbbVie |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALOX5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-28Phase 3 first posted: Ain Shams University, Nicorandil Oral Tablet + Placebo (NCT07730723)
- 2025-11-26Results posted on the registry: University of Oxford, Methotrexate + Sulfasalazine (NCT03739853)
- 2025-05-22Phase 3 first posted: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study from Bangladesh (NCT06985134)
- 2025-04-08Phase 3 first posted: University of Guadalajara, Will take 200mg/day magnesium oxide placebo. (NCT06915701)
- 2025-02-21Results posted on the registry: Boston Medical Center, SHINGRIX (NCT03591770)
- 2025-02-21Also stopped (terminated): Boston Medical Center, SHINGRIX (NCT03591770)
- 2025-01-09Results posted on the registry: University of Arizona, Sulfasalazine + Placebos (NCT03847311)
- 2024-09-19Phase 3 first posted: King Edward Medical University, standard treatment (NCT06594822)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision